
Conference Coverage
28 days ago
Is Pharma Moving Too Fast on AI Agents?about 1 month ago
LogiPharma 2026: CSafe on Right-Sizing Bulk Air Cargo Protectionabout 1 month ago
How Pharma Automation Cuts Human Touches and Error RiskLatest Content

Executive Conversations: How Patient Advocacy Is Shaping Channel Design

How Specialty Trade Deals Are Shifting Toward Patients

Executive Conversations: How Should Manufacturers Reevaluate Their Channel Strategy?

Pharma Pulse: FDA Launches Global Reliance Program

How Medicine Moves: The Invisible Infrastructure Behind Every Dose

Shorts










Podcasts
All News

In Episode 2, Part 2, Cheryl Allen, Nick Calla and Rena Goins discuss where traditional channel models break down as therapies grow more complex.

UPS' deal for Smartways Logistics adds a dedicated health care courier network in Australia and New Zealand to its Asia Pacific buildout.

The White House pulled Heidi Overton's FDA nomination a day before a Senate HELP vote, leaving acting Commissioner Kyle Diamantas in charge.

In Episode 2, Part 1, Cheryl Allen, Nick Calla and Rena Goins discuss whether today's channel models are ready for an increasingly complex pipeline.

APIIC's Brian Doty on how repurposing shuttered U.S. plants with advanced manufacturing could make domestic generic drug production viable.

In Episode 1, Part 4, Jon Hamrick, Rena Goins and Bob Cochran explain what separates trade teams seen as strategic partners from those that aren't.

Fragmented data is eroding trust in pharma insights, and AI raises the stakes. A four-step approach can help organizations pay down their “data debt.”

Thani Jambulingam, Ph.D., says MFN pricing, Section 232 tariffs and PBM reform will converge to shape how pharma launches and commercializes new drugs.

In this week’s Pharma Pulse, Lilly brings Zepbound and Foundayo to Hims & Hers, Swisslog Healthcare expands its Tenutō cold storage line, and FDA adds a NAION warning across the GLP-1 class.

In Episode 1, Part 3, Jon Hamrick, Rena Goins and Bob Cochran explain why specialty networks should start small and how to balance access, data and support.

In Episode 1, Part 2, Jon Hamrick, Bob Cochran and Rena Goins explain why trade belongs in commercial planning at least a year before launch.

CVS Health’s proposed separation of its retail pharmacy business from insurance and pharmacy benefit management raises a fundamental question: Will changing ownership improve pharmaceutical distribution, competition and patient access, or simply redistribute market power?

In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.

APIIC's Brian Doty says renovating shuttered US plants with advanced manufacturing is faster and cheaper than building new to reshore generics.

Joint clinical assessment, shifting HTA demands and pricing pressure are making launch the start of continuous evidence generation.















